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Botulinum toxin (BoTx) is a product of gram-positive anaerobic bacteria of the Clostridium 
genus. At present, seven serotypes (A to G) of BoTx have been identified. Each of them 
functions as a zinc-dependent endopeptidase that hydrolyzes peptide bonds within soluble 
N-ethylmaleimide-sensitive factor attaching protein receptors. BoTx affects proteins required 
for neurotransmitter release through presynaptic membranes. As a result, muscle weakness 
develops, or complete paralysis of the muscles occurs. These effects are not only limited 
to striated muscles but also may have impact on smooth muscles and secretory glands. The 
observation that BoTx can diffuse from the site of administration may indicate the possibility 
of direct or indirect influence of the toxin on the CNS. Consequently, the question arises: 
What is the mechanism of the central action of BoTx? Several mechanisms of such action 
have been proposed. However, recent findings showed that the most probable mechanism 
responsible for the central effects of BoTx action is its anterograde transport. In this review, 
we describe and discuss the most important aspects related to BoTx action on the CNS. 
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INTRODUCTION
Botulinum toxins (BoTxs) are produced by gram-
positive anaerobic bacteria of the Clostridium genus 
(Clostridium botulinum, Clostridium butyricum, and 
Clostridium baratii). These bacteria have been with 
mankind since the beginning of time. The interest 
of scientists in BoTx began at the end of the 18th 
century, when sausage poisoning in the German state 
of Wurttemberg was first described. A few years later, 
a German poet and district medical officer, Justin 
Kerner, published a complete description of food-
borne botulism symptoms. However, the work done 
by Kerner was not enough to identify the deadly 
pathogen, although it allowed researchers to conclude 
that the disease was closely related to consumption of 
processed meat. The first to identify and describe the 
pathogen was the German Professor of bacteriology at 
the University of Ghent, Emile Van Ermengem [1–3]. 
Later on, research on BoTxs led to the identification 
of their seven serotypes (A to G). The structure 
of these toxins and the mechanisms of their effects 
were described, which allowed researchers to begin 
the therapeutic use of BoTx. In 1989, the US Food 
and Drug Administration approved the use of BoTx 
type A in the treatment of strabismus, blepharospasm, 
hemifacial spasm, and cervical dystonia [4]. Nowadays 
BoTxs are  widely used both by the pharmaceutical 
industry and in cosmetic medicine/surgery. Also, many 
off-label uses of BoTx A are being developed. The list 
of medical conditions treated by BoTx administration 
is shown in Table 1. 
Structure of BoTx; the Mechanism and Effects. 
Each serotype of BoTx is formed by a 150 kDa 
single polypeptide chain that is posttranslationally 
proteolysed by endogenous proteases to a dichain 
structure. As a result, an active form of BoTx is 
composed of two polypeptide chains, a heavy 
chain (HC, 100 kDa) and a light chain (LC, 
50 kDa), which are connected by covalent disulfide 
and noncovalent bonds. The heavy chain of BoTx 
consists of two domains [5]. A C-terminal domain 
contributes to the binding of the BoTx molecule to 
membrane gangliosides and specific receptors, such as 
synaptotagmins I and II [6, 7]. An N-terminal domain, 
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on the other hand, allows BoTx to enter nerve cells by 
translocation [8, 9]. Once the light chain of BoTx is 
translocated into the neuron, it impairs the release of 
neurotransmitters affecting a multiple-step cascade of 
protein-protein interactions, which is as follows. The 
arrival of an action potential (AP) at the axon terminal 
activates voltage-gated calcium channels, causing an 
influx of localized calcium ions into the cell. This, 
in turn, according to the SNARE hypothesis, triggers 
interaction of synaptotagmins with SNARE proteins 
(soluble N-ethylmaleimide attachment to the protein 
receptor). These events lead to fusion of the synaptic 
vesicles with the presynaptic membrane within an 
active zone. Briefly, once calcium ions attach to 
synaptotagmins, binding of synaptobrevin (VAMP, 
vesicle-associated membrane protein) to SNAP-25 
and syntaxin is facilitated.  Then, Rab-mediated 
n-Sec1 dissociation from synataxin is observed. As 
a consequence, a core complex is formed.  Calcium-
dependent oligomerization of the core complex leads 
Medical conditions treated with botulinum toxin [34, 81-91]
Медичні показання для лікування з використанням ботулінового токсину [34, 81–90]
Conditions for which treatment with BoTx has been used
Movement disorders:
dystonia;
hemifacial spasm;
tremor;
tics;
bruxism;
re-innervation synkinesias;
myokymia;
neuromyotonia;
stiff person syndrome.
Hypersecretory disorders:
hyperhidrosis;
sialorrhea;
hyperlacrimation;
rhinorrhea.
Ophthalmic disorders:
strabismus, nystagmus;
exotropia, esotropia, entropium;
protective ptosis.
Pain:
neuropathic pain;
tension headache;
migraine;
myofacial pain;
musculoskeletal pain;
arthritis.
Pelvic ﬂoor and gastrointestinal disorders:
achalasia;
anal fissures;
detrusor-sphincter dyssynergia;
vesical sphincter spasms;
sphincter oddi spasms;
animus;
vaginismus.
Cosmetic applications:
muscular facial lines;
facial asymmetries.
Others:
eye-lid opening apraxia;
tetanus;
stuttering;
multiple sclerosis;
idiopathic bladder syndrome;
perioperative fixations in orthopedic surgery.
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to the formation of a fusion pore; the latter is stabilized 
by oligomerization of synaptotagmin I. As the result, 
the membrane collapses, and the vesicle content is 
released into the synaptic gap [10–12]. 
After the released neurotransmitters reach the 
postsynaptic membrane, they bind to postsynaptic 
receptors, ionotropic (ligand-gated ion channels) 
or metabotropic (receptors coupled to G proteins). 
This causes changes in the postsynaptic membrane 
permeability followed by a shift of the potential on 
the postsynaptic membrane. As a result, excitatory or 
inhibitory postsynaptic potentials (EPSPs and IPSPs, 
respectively) develop. If the postsynaptic membrane 
undergoes depolarization, an EPSP occurs, and this 
may lead to generation of an action potential (AP). 
A milestone in understanding the process described 
above was the following interpretation. The BoTx light 
chain functions as a zinc-dependent endopeptidase and 
hydrolyzes the SNARE protein complex [5]. Toxins 
of the B, D, F, and G types act on synaptobrevin [13–
16]. The serotypes A and E hydrolyze SNAP25, while 
the serotype C is able to degrade both SNAP25 and 
syntaxin [17, 18] (for review, see [5, 19–21]). As a 
result, neurotransmitter exocytosis is blocked at 
different levels. Due to SNAP25 hydrolysis, BoTx type 
A blocks the post-docking priming step of exocytosis. 
Serotypes D, E, and F, on the other hand, prevent the 
formation of the fusion complex, while BoTxs B, C, 
and G uncouple fusion particles from the vesicle or 
plasma membrane [22].
Regardless of the hydrolyzed SNARE-type protein, 
the effect of BoTx on the nerve cell is the dose-
dependent inhibition of neurotransmitter release 
through the presynaptic membrane (mainly that of 
acetylcholine). This causes inhibition of striated-
muscle neuromuscular junctions with consequent 
muscle weakness and possible complete paralysis. 
Further experiments have shown that the action of 
BoTx is not limited to acetylcholine release and 
striated muscle weakness, but also influences the 
secretion of neurotransmitters, including glutamate, 
GABA, aspartate, met-enkephalin, noradrenaline [23, 
24], serotonin [25], and glycine [26]. These effects 
cause the respective electrophysiological alterations 
[27] and can influence smooth muscles and secretory 
glands [28]. 
Initially, it was thought that the BoTx-specific 
effects are local. However, it was shown that BoTxs 
are able to diffuse and act on other remote tissues, 
perhaps even on those of the CNS, causing long-lasting 
structural and functional changes in the vicinity of the 
site of BoTx administration [29–32]. 
As was mentioned, therapeutics containing BoTx A 
(e.g., Botox ® and Dysport ®) or BoTx B (Myobloc®) 
are widely used in the treatment of medical conditions 
associated with excessive activity of the striated 
muscles, smooth muscles, or secretory glands, and 
also in cosmetic medicine for wrinkle reduction. 
Additionally, there are attempts to use BoTxs of types 
A or B in the treatment of off-label medical conditions. 
With increase in the therapeutic use of BoTx A and 
BoTx B, an increased number of reports concerning 
side effects of BoTx administration is observed. 
Among the most frequently mentioned, there are 
markers of neurological impairment (impaired vision, 
conjunctival irritation, reduced sweating, swallowing 
difficulties, mouth dryness, and others) [33, 34]. This 
may suggest that, in addition to the peripheral action 
correlated with side effects of toxin administration, 
BoTx is likely to directly affect the nervous system by 
influencing peripheral or central pathways.
Central Effects of BoTx Administration. The 
hypothesis of the central BoTx action is consistent 
with the results of research conducted in the 1960–
1970s. In 1963, Tyler [35] observed changes in 
the Hoffman reflex (H reflex) in a patient with 
botulism; a few years later, Polley et al. [36] found 
BoTx-related changes in cortical electrical activity 
in monkeys. Although the above authors [35, 36] 
showed that peripherally administered BoTx can 
cause symptoms associated with the CNS, there was 
no direct evidence for the possibility of the presence 
of BoTx in the CNS structures. The lack of this direct 
evidence made it impossible to  link neurological 
effects of peripheral administration of BoTx with 
the appearance of the toxin in the CNS. One of the 
first research groups to prove that the peripherally 
administered BoTx can be transported to the brain 
or spinal structures was that of Wiegand et al. [31]. 
In their experiments, radioactively labeled BoTx was 
injected into the cat m. gastrocnemius. As a result, a 
distal-proximal gradient of radioactivity in the sciatic 
nerve developed. In addition, ipsilateral ventral roots 
innervating the injected muscle exhibited significantly 
higher levels of radioactivity than ventral roots of the 
contralateral (control) side. Direct stimulation of the 
muscle injected with BoTx type A caused an increase 
in the radioactivity level in the spinal half-segments 
ipsilateral to the injected muscle [31]. Unfortunately, 
the experiments using radioactively labeled BoTx 
type A demonstrated only that the peripherally 
administered BoTx A is, in principle, able to reach the 
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CNS. In addition, as in the case of all animal studies, it 
was impossible to rule out the influence of anatomical 
(e .g. ,  muscle innervat ion)  and physiological 
(e.g., metabolic rate) differences on the results 
obtained. Similarly, the administered BoTx dose 
was significantly higher than the doses used in the 
treatment of humans. Taking this into consideration, 
we doubt that BoTx type A found by Wiegand et al. 
in the CNS [31] possessed significant enzymatic 
activity, and that the observed results reflect changes 
occurring after peripheral administration of the toxin 
in humans. To resolve this, a few experimental and 
clinical studies were conducted. As a result, the main 
CNS structures, whose functions can be modulated by 
peripherally administered BoTx, have been identified. 
Among them, are the spinal cord, brainstem structures, 
and motor cortex [37-40]. 
The influence of peripherally injected BoTx 
on the spinal cord was confirmed by a series of 
electrophysiological experiments carried out by 
Hamjian and Walker [41]. Recording from the extensor 
digitorum brevis (EDB) muscle before and after 
administration of 10 U BoTx A in ten human subjects 
demonstrated that i.m. injection of the toxin caused a 
transient increase in the F-wave amplitude and a long-
term increase in the F/M amplitude ratio. The authors 
suggested that the observed changes may result from 
a tetanus-like inhibition of acetylcholine release from 
Renshaw cells and reduced inhibition of ventral horn 
cells. Moreover, since the peripheral silent period 
remained unchanged, this could indicate that BoTx 
type A did not influence afferent inputs from muscle 
spindle receptors [41].
Moreno-Lopez et al. [42] tried to estimate the 
impact of BoTx type A on the brainstem functions. 
The authors recorded dose-dependent changes in 
impulsation in cranial nerves after administration of 
BoTx A to the lateral rectus muscle of the cat’s eye. 
A single administration of the type A toxin in a dose 
of 3 ng/kg changed the discharge pattern of abducens 
motoneurons for three months. Based on these results, 
it was hypothesized that the effect of a high dose of 
BoTx A may be associated with the toxin transport 
from early endosomes via the trans-Golgi network and 
intra-Golgi transport to the endoplasmic reticulum 
by retrograde transport [43] or due to transneuronal 
changes [42]. Slawek and Reclawowicz [44] attempted 
to assess the possible central action of BoTx type A 
by recording auditory and somatosensory EPs in 
patients with cervical dystonia. The patients taking 
part in the experiment received BoTx A injections into 
the mm. sternocleidomastoideus (splenius capitis), 
trapezius, and lavator scapulae. In 4 to 6 weeks post-
injection, examination of the brainstem auditory 
evoked responses (BAERs) and somatosensory evoked 
potentials (SSEPs) induced by stimulation of upper 
limbs was conducted. The results were compared 
with those obtained before BoTx A injections, and 
no statistically significant differences were observed. 
This may suggest that a direct central action of BoTx 
type A does not exist, and the neurological effect 
observed after BoTx administration may result 
from the impact of toxin on somatic elements of the 
peripheral nervous system [44]. 
In order to determine the impact of the toxin on the 
motor cortex, long-latency reflexes (LLRs) induced 
by electrical nerve stimulation were examined. After 
electrical stimulation of the median nerve, two types 
of EMG responses could be recorded, LLR1 and 
LRR2. The LLR1 is analogous to the stretch reflex, 
while the LLR2 is considered to reflect the activity of 
a cortical generator including the supplementary motor 
area. Naumann and Reiners [45] noted that patients 
with idiopathic focal dystonia manifested after BoTx A 
injections a significant reduction of the LLR2 
amplitude on the clinically affected side, suggesting 
that BoTx A is capabile of modifying afferent outputs 
coming from the injected muscle and of modulating 
the central motor pattern in focal dystonia [45]. 
An another way to determine the cortical aspects 
of BoTx peripheral administration was to use 
transcranial magnetic stimulation (TMS) and analysis 
of motor evoked potentials (MEPs). Byrnes et al. 
[46] used this approach to plot an electrical activity 
map of primary motor cortex projections to the hand 
and forearm muscles in patients with writer’s cramp 
during isometric contractions. It was found that i.m. 
BoTx type A injections did not cause any long-term 
improvement of the electrical activity map. However, 
BoTx A treatment was accompanied by transient 
reversal changes of abnormalities in the cortical 
electrical activity map, and the duration of such shifts 
depended on the clinical improvement associated 
with administration of the toxin. After the BoTx A 
effect declined, the cortical electrical activity map 
returned to the state observed before the treatment. 
These results suggest that changes within the primary 
motor cortex occurring in patients with dystonia may 
be due to abnormalities in afferent inputs, which can 
be temporarily modulated by i.m. administration of 
BoTx type A [46]. Experiments carried out on animals 
also supported a possibility of motor reorganization 
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following BoTx A injections. Using intracortical 
microstimulations of the vibrissa motor cortex area, 
Franchi [47] showed that BoTx A administration into a 
rat vibrissal pad caused a decrease in the dimensions of 
ipsilateral vibrissa representations in both hemispheres 
with simultaneous expansion of the forelimb and 
eye representations. This resulted in modulation of 
the forelimb, eye, and neck movements induced by 
electrical stimulation inside the former vibrissa region 
[47]. 
Other CNS elements that may be affected by the 
toxin are the structures involved in higher functions of 
the CNS, in particular the unimodal and heteromodal 
cortices, as well as structures of the paralimbic and 
limbic systems [48]. Although Haaland and Davis 
[50] did not succeed in proving the influence of BoTx 
on memory in patients with botulism [50], there are 
a few reports confirming such action. Experiments 
with positron emission tomography (PET) conducted 
on a group of patients diagnosed with adductor 
spasmodic dysphonia (ADSD) showed that speech-
related responses of the CNS regions, involved in 
pathophysiology of the disorder, were significantly 
affected after administration of BoTx A [50]. In these 
experiments, Ali et al. [50] compared the results of 
PET examination in the course of the narrative speech 
test, narrative whispering test, and during a rest period. 
This was performed in a group of patients before and 
after treatment with unilateral injection of BoTx type A 
into the left thyroarytenoid muscle (16 ± 2.2 U, five 
patients) or injection of the toxin into both left and 
right thyroarytenoid muscles (2.9 ± 0.3 U, four 
patients). Additionally, to determine CNS markers of 
spasmodic dysphonia, the PET scan results of ADSD 
patients were compared with the results of healthy 
volunteers. Analysis of results of the narrative and 
whispering speech tasks revealed that BoTx treatment 
decreased the activity in the regions where responses 
demonstrated hyperactivity in the ADSD patients, 
including the right dorsal precentral gyrus, cerebellar 
hemispheres, vermis, primary auditory cortex, anterior 
cingulate cortex, and right anterior insula. The toxin 
administered also augmented the activity in the regions 
hypoactive in dysphonic patients. Among these regions 
were the dorsal postcentral gyrus, right anterior 
audidtory association cortex, posterior supramarginal 
gyrus, and posterior middle temporal gyrus, i.e., 
the parts of the unimodal and heteromodal sensory 
association areas. Moreover, the authors noticed a 
correlation between most regions where the BoTx 
treatment exerted its effects (increased or decreased 
activity) and clinical improvement. Although the toxin 
influenced a wide range of the CNS regions, it did not 
affect the activity in other regions, which were hypo- 
or hyperactive in ADSD. Among these regions, the 
supplementary motor area, anterior middle temporal 
gyrus, periaqueductal gray matter, posterior auditory 
association cortex, and right ventral precentral gyrus 
should be mentioned. According to the authors, these 
findings suggest that peripherally adminstered BoTx 
may, in fact, influence CNS activity. Unfortunately, the 
validity of these results can be brought into question. 
The obtained differences between healthy volunteers 
and patients may not be determined by the illness 
itself but reflect compensatory events or secondary 
responses to a primary pathophysiological process. 
This would explain the decrease of hyperactivity in 
the motor areas of people with ADSD, which are not 
typically associated with direct control of the oral 
and laryngeal muscles. Another troubleshooting issue, 
besides differentiation of the real impact of the toxin 
on spasmodic dysphonia pathophysiology related to the 
influence on compensatory mechanisms, is the dose and 
the side of toxin administration [52]. As was mentioned, 
five of nine patients received single unilateral injections 
of BoTx into the left thyroarytenoid muscle, while 
the remaining four patients were bilaterally injected 
with the toxin into both left and right thyroarytenoid 
muscles. Since it has been proven that the toxin’s action 
is dose-dependent [51], it seems to be unlikely that 
the dose and side of administration did not affect the 
observed clinical improvement and PET scans in the 
above-mentioned experiments. 
Besides human studies, the influence of BoTx on 
higher functions of the CNS seems to be confirmed by 
animal studies. Ando et al. [52] used administration 
of BoTx B to the entorhinal cortex to develop the 
rat model of dementia. Tests in the Hebb–Williams 
maze, AKON-1 maze, and a continuous alternation 
task in the T maze revealed the cognitive impairment 
in old rats and changes in learning and memory in 
adult rats. In addition, the analysis of induction of 
long-term potentiation (LTP) indicated significant 
suppression of this process in old rats [52]. Similar 
changes of the cognitive functions in CD1 mice after 
intracerebroventricular (i.c.v.) injection of the toxin 
types A and B were observed. During conditioning 
of active avoidance and of object recognition in the 
respective tests, BoTx-treated mice showed a reduced 
capacity to discriminate a novel object within a 
familiar environment [53]. In other experimental 
model with i.c.v. injections of the toxin type A 
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in rats, the Rotarod and Morris water maze tests 
were used to evaluate motor activity  and spatial 
memory, respectively. The temporal characteristics 
of spatial memory impairment obtained during the 
experiment suggested a slower onset (during up to 
3 months after i.c.v. BoTx A injections) and a long-
term spatial memory disorder [54]. These results 
contradict the existing knowledge on the temporal 
characteristics of BoTx action. In most clinical cases, 
a measurable effect of BoTx action appears 3 to 
30 days after administration [55]. In an animal model, 
products of BoTx A proteolysis were confirmed in the 
hippocampus 3 days after intrahippocampal injections 
[56]. 
Taken together, the results of experimental and 
clinical observations suggest that, in principle, the 
peripherally administered toxin can affect the CNS 
functions. Due to these results, a question arises: What 
is the mechanism of BoTx’s central action? 
Possible Mechanisms of the Central Action of 
BoTx. Currently, several possible major mechanisms 
of BoTx central action have been hypothesized. One 
of the most probable mechanisms of central action 
is related to blocking of acetylcholine release from 
γ-motoneurons connected with intrafusal muscle fibre 
endings. This leads to reduction of the input from 
Ia afferents with possible changes in presynaptic 
inhibitory effects of Ia afferents of antagonistic 
muscles or to reorganization of the cortical motor 
maps. The second mechanism involves the blockade 
of neuromuscular connections between α-motoneurons 
and extrafusal muscle fibers inducing plastic changes 
in motoneurons. Another possibility is transportation 
of the toxin from the cell body to axon terminals by 
anterograde transport  followed by BoTx conveyance 
from one cell to another by membrane-bound carriers 
(a process called transcitosis) [38, 57]. Antonucci et 
al. [56] conducted an experiment in which BoTx type 
A was introduced in the hippocampus of C57BL/6N 
mice and Sprague–Dawley rats. To establish the 
central effect of such intrahippocampal injections, 
the emergence of SNAP25 breakdown products was 
recorded by immunohistochemical staining. The 
staining procedure was preceded by Western blot 
experiments; the latter demonstrated that polyclonal 
antibodies used in the experiment were recognized 
to be specifically cleaved by BoTx A or BoTx E 
SNAP- 25 and not by the whole protein. Interestingly, 
the SNAP25 hydrolysis product was found in a 
contralateral hemisphere. The staining spots were 
observed in the neuropil of superficial layers II-III. 
Since the II/III-layer neurons of the entorhinal cortex 
project to the hippocampus, retrograde transport can be 
assumed to be realized. In the same study, injections 
of BoTx toxin type A into a rat whisker muscle were 
performed. As a result, the SNAP25 proteolysis 
products appeared in the facial nucleus [56]. These 
results are strongly supported by the work by Restani 
et al. [58], who performed a multistep experiment on 
the rat visual pathways. Using an immunostaining 
technique and Western blotting, the authors managed 
to confirm the presence of BoTx A-truncated SNAP25 
in the retinorecipient layer of the colliculus superior, 
as well as to rule out the possibility of the systemic 
spread of the toxin. Furthermore, the intraocular 
injection of colchicine revealed lack of BoTx A- 
truncated SNAP25 in the tectum after blockade of 
the anterograde transport. This fact, together with 
the lack of immunorectivity in retinal terminals after 
double immunostaining by markers of excitatory and 
inhibitory synapses, strongly suggests transcitosis and 
anterograde transport of the toxin. Since it could be 
argued that the conducted experiments showed the 
anterograde transport of cleaved SNAP25 rather than 
that of BoTx A itself, Restani et al. [58] combined 
intravitreal administration of toxin type A followed 
by section of the optic nerve with BoTx E intratectal 
injection. Similarly to BoTx A, the type-E toxin 
cleaves SNAP25. As a result, a 26-residue fragment 
is removed, while the BoTx type A removes only nine 
residues from the same region. Additionally, the action 
of BoTx E is short-lasting [59]. As was expected, the 
amount of BoTx A-truncated SNAP25 in the superior 
colliculus initially decreased. After the completion 
of BoTx type E effects, the catalytic activity of 
BoTx A, however, reappeared by means of increased 
BoTx A-truncated SNAP25, undeniably showing that 
toxin type A is transported anterogradely to the CNS 
structures [58]. Results presented by Bogucki [60], on 
the other hand, undermine the possibility of BoTx A 
retrograde transport to the CNS elements. To eliminate 
the possibility of BoTx A retrograde transport, 
peripheral nerve dissection was performed in an 
animal model. Single muscle fiber-EMG confirmed the 
presence of neuromuscular transmission disturbance 
in distant muscles, suggesting that hematogenic 
spreading of toxin type A occurs [60]. 
The third proposed mechanism seems to be the 
least likely since it implies toxin transport through the 
blood-brain barrier (BBB). Although Boroff and Chen 
[61] showed the presence of BoTx A in parenchyma 
and brain blood vessels after peripheral administration 
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in mice [62], the molecular size of botulinum toxin 
(150 kDa) makes the diffusion of BoTx through the 
BBB poorly probable.
Despite obtained evidence confirming the central 
action of BoTx and a few proposed mechanisms 
of such action,  it seems that new experimental 
approaches in this respect are needed.
Antinociceptive Action of BoTx – New Insight into 
its Central Action. Unexpectedly, a new insight into 
the central effect of BoTx type A was provided due to 
explanation of an antinociceptive effect of the toxin. It is 
well known that pain transmission depends on the release 
of certain neurotransmitters and neuropeptides, including 
glutamate, substance P (SP), and calcitonin gene-related 
peptide (CGRP) [62]. Since it was shown that BoTx A 
inhibits the release all these agents (glutamate [63], 
substance P [64] and calcitonin gene-related peptide 
[65]), it seems reasonable to conclude that BoTx type 
A is capable of inducing the antinonciceptive effect 
by blocking the release of the above neurotransmitters 
and neuropeptides. This “pain relief” action does not 
always correlate with muscle weakness (if such occurs) 
and strongly suggests that the antinonciceptive BoTx 
A action depends on a mechanism differing from that 
responsible for muscle weakness. In subjects diagnosed 
with a muscle-centered temporomandibular disorder, i.m. 
injection of BoTx type A caused weakness in chewing 
muscles and reduction in subjective pain sensation. 
Eight weeks after toxin administration, the muscle power 
returned to baseline, while pain relief was maintained 
[67]. Similarly, Tarsy and First [68] found that the 
treatment of cervical dystonia with BoTx type A induced 
pain relief without improvement in the head positioning 
[67]. Further evidence for the antinonciceptive action 
of BoTx A has been provided using experimental 
inﬂammatory pain models. Pretreatment with BoTx type 
A reduced the formalin-induced grooming response [69] 
and licking/lifting behavior within the second phase of 
inﬂammatory pain [69] independently of the dose and 
route of administration [70, 71]. Also, pretreatment 
with BoTx A in carrageenan- and capsaicin-induced 
inflammatory pain models induced suppression 
of thermal and mechanical hyperalgesia [72, 73]. 
Neuropathic pain animal models confirmed the analgesic 
effect of BoTx type A. In the neuropathy model induced 
by sciatic nerve transection, single subcutaneous (s.c.) 
administration of BoTx A reduced or even completely 
abolished thermal and mechanical hyperalgesia [74]. 
In the chronic constriction-injury model of neuropathic 
pain, single intraplantar injection of the toxin reduced 
mechanical allodynia in mice [75] and rats [76], as 
well as thermal hyperalgesia [76] and allodynia [77] 
in rats. The peripheral polyneuropathic rat model also 
provided information on the analgesic effect of BoTx 
type A administration. In this model, paclitaxel-induced 
mechanical hyperalgesia was inhibited in both paws after 
BoTx A administration ipsilaterally to the paclitaxel 
injection side. The threshold for paw withdrawal pressure 
3 days after the toxin injection was comparable with that 
observed in rats injected with saline [72]. 
It is well known that i.p. injection of streptozotocin 
induces diabetic neuropathy, which results in increased 
sensitivity to mechanical and thermal stimuli three 
weeks after injection. Administration of BoTx type A not 
only reduced mechanical hypersensitivity ipsilaterally 
to the injection side, but contralaterally as well. The 
antinonciceptive effect of the toxin towards thermal 
stimuli was observed only on the ipsilateral side [71]. 
It is worth mentioning that the antinonciceptive effect 
of BoTx type A administration in all described pain 
models was observed without any changes in the muscle 
power, once again suggesting the existence of a different, 
than muscle weakness-inducing, mechanism of BoTx 
A action. If so, the question of the nervous system 
structures involved in BoTx type A action rearises. As 
was proposed by Pavone and Luvisetto [78], BoTx A 
can exert its action by inhibiting the neurotransmitter 
and/or neuropeptide release from nonciceptive 
endings. This, in turn, reduces peripheral and/or central 
sensization, as well as blocks neurotransmission 
from central terminals of nonciceptive afferents. The 
possibility of retrograde transport also should be taken 
into consideration [79]. To establish the BoTx A side 
of action, a series of experiments on the toxin-related 
antinonciceptive effect was conducted. Bach-Rojecky 
and Lackovic [79] employed acidic saline-induced pain, 
colchicine administration, and sciatic nerve transection 
to demonstrate the central analgesic action of BoTx A. In 
these experiments, unilateral intramuscular injection of 
an acidic saline into the rat’s hindpaw induced bilateral 
mechanical hyperalgesia, which was  latter reduced in 
both hindpaws by s.c. toxin administration. When BoTx 
type A was injected contralaterally to the pain induction 
side, the antinonciceptive effect was observed only on 
the above side. To eliminate the possibility of peripheral 
desensitization, the toxin was ipsilaterally injected 
after acidic saline administration into the sciatic nerve.
Then, this nerve was cut distally to the side of injection, 
preventing BoTx A appearance in peripheral nerve 
endings. Surprisingly, a significant antinonciceptive 
effect on the contralateral side was induced after such 
BoTx type A injection. The authors hypothesized that 
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the decrease in mechanical hyperalgesia might reﬂect 
the central action of the toxin after its retrograde 
transport. To confirm this possibility, BoTx A injection 
was followed by colchicine administration. Both 
substances were injected ipsilaterally to the acidic 
saline administration side. Due to colchicine-induced 
blockade of the axonal transport, the toxin effect was 
abolished both ipsilaterally and contralaterally. The 
final evidence for the central BoTx type A action was 
the effect of intrathecal toxin injection, which resulted 
in the abolishment of mechanical hypersensitivity on 
both sides [80]. In another study, colchicine injection 
into the trigeminal ganglion decreased the analgesic 
effect of BoTx A in the formalin-induced pain model. 
Additionally, immunostaining revealed the presence of 
cleaved SNAP25 in the dorsal horn of the ipsilateral 
trigeminal nucleus caudalis after BoTx type A application 
into the rat whisker pad [68]. 
Taken together, these data strongly suggest a 
possibility ot the central action of BoTx A based on 
retrograde transport of the latter. However, additional 
work should be done to clarify possible BoTx-induced 
modifications of the CNS functions.
This publication is a review paper; it was not associated 
with any experiments on animals or tests involving human 
subjects; therefore, it does not require confirmation of compli-
ance with existing ethical standards from this aspect.
The authors of this communication, M. Galazka, 
D. Soszynski, and K. Dmitruk, confirm the absense of 
any conflict related to comercial or financial interests, to 
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Р е з ю м е
Ботуліновий токсин (BoTx) є продуктом життєдіяльно- 
сті грампозитивних бактерій роду Clostridium. На теперіш-
ній час ідентифіковано сім серотипів BoTx (A–G). Всі вони 
функціонують як цинкзалежні ендопеотидази, що гідролізу-
ють пептидні зв’язки з розчинним N-етилмалеімідчутливим 
фактором, контактуючим з протеїновими рецепторами. 
BoTx впливає на протеїни, необхідні для вивільнення ней- 
ротрансмітерів через пресинаптичні мембрани. Як резуль-
тат, розвиваються м’язова слабкість або повний параліч 
м’язів. Такі ефекти не обмежуються поперечносмугастими 
м’язами, вони виявляються також у гладеньких м’язах та се-
креторних залозах. Як спостерігалося, BoTx може дифунду-
вати від місця свого введення; це може вказувати на прин-
ципову можливість прямих або непрямих впливів токсину 
на ЦНС. Відповідно, виникає питання: яким є механізм цен-
тральної дії BoTx. Було запропоновано декілька гіпотез про 
механізми такої дії. Результати нещодавніх досліджень, од-
нак, свідчать про те, що найбільш вірогідним механізмом, 
відповідальним за центральні ефекти BoTx, є його дія на 
антероградний транспорт. У нашому огляді ми описуємо та 
обговорюємо найбільш важливі аспекти дії BoTx на ЦНС.  
REFERENCES
1.  M. Cherington, “Clinical spectrum of botulism,” Muscle 
Nerve, 21, No. 6, 701-710 (1998).
2.  F. J. Erbguth, “Historical notes on botulism, Clostridium 
botulinum, botulinum toxin, and the idea of the therapeutic 
use of the toxin,” Mov. Disord., 19, Suppl 8, 2-6 (2004).
3.  J. Jankovic and M. F. Brin, “Botulinum toxin: historical 
perspective and potential new indications,” Muscle Nerve, 6, 
Suppl., 129-145 (1997).
4.  M. F. Lew, “Review of the FDA-approved uses of botulinum 
toxins, including data suggesting efficacy in pain reduction,” 
Clin. J. Pain, 18, Suppl. 6, 142-146 (2002).
5.  B. R. Singh, “Botulinum neurotoxin structure, engineering, 
and novel cellular trafficking and targeting,” Neurotox. Res., 
9, Nos. 2/3, 73-92 (2006).
6.  M. Dong, F. Yeh, W. H. Tepp, et al., “SV2 is the protein 
receptor for botulinum neurotoxin A,” Science, 312, No. 5773, 
592-596 (2006).
7.  M. Kitamura, K. Takamiya, S. Aizawa, and K. Furukawa, 
“Gangliosides are the binding substances in neural cells for 
tetanus and botulinum toxins in mice,” Biochim. Biophys. Acta, 
1441, No. 1, 1-3 (1999).
8.  A. Fischer, D. J. Mushrush, D. B. Lacy and M. Montal, 
“Botulinum neurotoxin devoid of receptor binding domain 
translocates active protease,” PLoS Pathog., 4, No. 12, 
e1000245 (2008).
9.  M. Montal, “Translocation of botulinum neurotoxin light 
chain protease by the heavy chain protein-conducting 
channel,” Toxicon, 54, No. 5, 565-569 (2009).
10. T. W. Koh and H. J. Bellen, “Synaptotagmin I, a Ca2+ sensor for 
neurotransmitter release,” Trends Neurosci., 26, No. 8, 413-
422 (2003).
11. Y. A. Chen and R. H. Scheller, “SNARE-mediated membrane 
fusion,” Nat. Rev. Mol. Cell Biol., 2, No. 2, 98-106 (2001).
12. J. Rizo and T. C. Sudhof, “Snares and Munc18 in synaptic 
vesicle fusion,” Nat. Rev. Neurosci., 3, No. 8, 641-653 (2002).
13. R. Pellizzari, S. Mason, C. C. Shone, and C. Montecucco, “The 
interaction of synaptic vesicle-associated membrane protein/
synaptobrevin with botulinum neurotoxins D and F,” FEBS 
Lett., 409, No. 3, 339-342 (1997).
14. G. Schiavo, F. Benfenati, B. Poulain, et al., “Tetanus and 
botulinum-B neurotoxins block neurotransmitter release by 
proteolytic cleavage of synaptobrevin,” Nature, 359, No. 6398, 
832-835 (1992).
NEUROPHYSIOLOGY / НЕЙРОФИЗИОЛОГИЯ.—2015.—T. 47, № 4388
M. GALAZKA, D. SOSZYNSKI, and K. DMITRUK
15. G. Schiavo, C. C. Shone, O. Rossetto, et al., “Botulinum 
neurotoxin serotype F is a zinc endopeptidase specific for 
VAMP/synaptobrevin,” J. Biol. Chem., 268, No. 16, 11516-
11519 (1993).
16. G. Schiavo, C. Malizio, W. S. Trimble, et al., “Botulinum G 
neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala 
peptide bond,” J. Biol. Chem., 269, No. 32, 20213-20216 
(1994).
17. V. V. Vaidyanathan, K. Yoshino, M. Jahnz, et al., “Proteolysis 
of SNAP-25 isoforms by botulinum neurotoxin types A, C, and 
E: domains and amino acid residues controlling the formation 
of enzyme-substrate complexes and cleavage,” J. Neurochem., 
72, No. 1, 327-337 (1999).
18. G. Schiavo, A. Santucci, B. R. Dasgupta, et al., “Botulinum 
neurotoxins serotypes A and E cleave SNAP-25 at distinct 
COOH-terminal peptide bonds,” FEBS Lett., 335, No. 1, 99-
103 (1993).
19. L. L. Simpson, “Identification of the major steps in botulinum 
toxin action,” Annu. Rev. Pharmacol. Toxicol., 44, 167-193 
(2004).
20. G. Schiavo, M. Matteoli, and C. Montecucco, “Neurotoxins 
affecting neuroexocytosis,” Physiol. Rev., 80, No. 2, 717-766 
(2000).
21. A. T. Brunger and A. Rummel, “Receptor and substrate 
interactions of clostridial neurotoxins,” Toxicon, 54, No. 5, 
550-560 (2009).
22. Y. Humeau, F. Doussau, N. J. Grant, and B. Poulain, “How 
botulinum and tetanus neurotoxins block neurotransmitter 
release,” Biochimie, 82, No. 5, 427-446 (2000).
23. H. T. McMahon, P. Foran, J. O. Dolly, et al., “Tetanus toxin 
and botulinum toxins type A and B inhibit glutamate, gamma-
aminobutyric acid, aspartate, and met-enkephalin release from 
synaptosomes. Clues to the locus of action,” J. Biol. Chem., 
267, No. 30, 21338-21343 (1992).
24. E. Habermann, H. Muller, and M. Hudel, “Tetanus toxin and 
botulinum A and C neurotoxins inhibit noradrenaline release 
from cultured mouse brain,” J. Neurochem., 51, No. 2, 522-527 
(1988).
25. R. Nakov, E. Habermann, G. Hertting, et al., “Effects of 
botulinum A toxin on presynaptic modulation of evoked 
transmitter release,” Eur. J. Pharmacol., 164, No. 1, 45-53 
(1989).
26. N. Akaike, Y. Ito, M. C. Shin, et al., “Effects of A2 type 
botulinum toxin on spontaneous miniature and evoked 
transmitter release from the rat spinal excitatory and inhibitory 
synapses,” Toxicon, 56, No. 8, 1315-1326 (2010).
27. Y. Bozzi, L. Costantin, F. Antonucci, and M. Caleo, “Action 
of botulinum neurotoxins in the central nervous system: 
antiepileptic effects,” Neurotox. Res., 9, Nos. 2/3, 197-203 
(2006).
28. U. Wollina, “Botulinum toxin: Non-cosmetic indications and 
possible mechanisms of action,” J. Cutan. Aesthet. Surg., 1, 
No. 1, 3-6 (2008).
29. M. Yaraskavitch, T. Leonard, and W. Herzog, “Botox produces 
functional weakness in non-injected muscles adjacent to the 
target muscle,” J. Biomech., 41, No. 4, 897-902 (2008).
30. S. K. Grimston, M. J. Silva, and R. Civitelli, “Bone loss after 
temporarily induced muscle paralysis by Botox is not fully 
recovered after 12 weeks,” Ann. New York Acad. Sci., 1116, 
444-460 (2007).
31. H. Wiegand, G. Erdmann, and H. H. Wellhoner, “125I-labelled 
botulinum A neurotoxin: pharmacokinetics in cats after 
intramuscular injection,” Naunyn-Schmiedeberg ҆ s  Arch. 
Pharmacol., 292, No. 2, 161-165 (1976).
32. D. B. Matic, T. Y. Lee, R. G. Wells, and B. S. Gan, “The effects 
of botulinum toxin type A on muscle blood perfusion and 
metabolism,” Plast. Reconstr. Surg., 120, No. 7, 1823-1833 
(2007).
33. D. Dressler and R. Benecke, “Autonomic side effects of 
botulinum toxin type B treatment of cervical dystonia and 
hyperhidrosis,” Eur. Neurol., 49, No. 1, 34-38 (2003).
34. R. M. Bauer, C. Gratzke, A. Roosen, et al., “Patient-reported 
side effects of intradetrusor botulinum toxin type A for 
idiopathic overactive bladder syndrome,” Urol. Int., 86, No. 1, 
68-72 (2011).
35. H. R. Tyler, “Botulinus toxin: effect on the central nervous 
system of man,” Science, 139, 847-848 (1963).
36. E. H. Polley, J. A. Vick, H. P. Ciuchta, et al., “Botulinum toxin, 
type A: Effects on central nervous system,” Science, 147, No. 
3661, 1036-1037 (1965).
37. M. Caleo and G. Schiavo, “Central effects of tetanus and 
botulinum neurotoxins,” Toxicon, 54, No. 5, 593-599 (2009).
38. M. Caleo, F. Antonucci, L. Restani, and R. Mazzocchio, “A 
reappraisal of the central effects of botulinum neurotoxin 
type A: by what mechanism?” J. Neurochem., 109, No. 1, 
15-24 (2009).
39. A. Curra, C. Trompetto, G. Abbruzzese, and A. Berardelli, 
“Central effects of botulinum toxin type A: evidence and 
supposition,” Mov. Disord., 19, Suppl. 8, 60-64 (2004).
40. G. Abbruzzese and A. Berardelli, “Neurophysiological 
effects of botulinum toxin type A,” Neurotox. Res., 9, Nos. 2/3, 
109-114 (2006).
41. J. A. Hamjian and F. O. Walker, “Serial neurophysiologi- 
cal  s tudies of  intramuscular  botul inum-A toxin in 
humans,” Muscle Nerve, 17, No. 12, 1385-1392 (1994).
42. B. Moreno-Lopez, A. M. Pastor, R. R. de la Cruz, and 
J. M. Delgado-Garcia, “Dose-dependent, central effects 
of botulinum neurotoxin type A: a pilot study in the alert 
behaving cat,” Neurology, 48, No. 2, 456-464 (1997).
43. J. Zhang, N. Naslavsky, and S. Caplan, “EHDs meet the 
retromer: Complex regulation of retrograde transport,” Cell 
Logist., 2, No. 3, 161-165 (2012).
44. J. Slawek and D. Reclawowicz, “The central action of 
botulinum toxin type A assessed by brain auditory and 
somatosensory evoked potentials,” Neurol. Neurochir. Pol., 
38, No. 2, 93-99 (2004).
45. M. Naumann and K. Reiners, “Long-latency reflexes of hand 
muscles in idiopathic focal dystonia and their modification 
by botulinum toxin,” Brain, 120 (Part 3), 409-416 (1997).
46. M. L. Byrnes, G. W. Thickbroom, S. A. Wilson, et al., “The 
corticomotor representation of upper limb muscles in writer’s 
cramp and changes following botulinum toxin injection,” 
Brain, 121 ( Part 5), 977-988 (1998).
47. G. Franchi, “Time course of motor cortex reorganization 
following botulinum toxin injection into the vibrissal pad 
of the adult rat,” Eur. J. Neurosci., 16, No. 7, 1333-1348 
(2002).
48. M. M. Mesulam, “From sensation to cognition,” Brain, 121 
(Part 6), 1013-1052 (1998).
49. K. Y. Haaland and L. E. Davis, “Botulism and memory,” Arch. 
Neurol., 37, No. 10, 657-658 (1980).
50. S. O. Ali, M. Thomassen, G. M. Schulz, et al., “Alterations 
in CNS activity induced by botulinum toxin treatment 
in spasmodic dysphonia: an H215O PET study,” J. Speech 
NEUROPHYSIOLOGY / НЕЙРОФИЗИОЛОГИЯ.—2015.—T. 47, № 4 389
CENTRAL ACTION OF BOTULINUM TOXIN TYPE A – IS IT POSSIBLE?
Lang. Hear. Res., 49, No. 5, 1127-1146 (2006).
51. J. V. Cichon, Jr., T. V. McCaffrey, W. J. Litchy, and 
J. L. Knops, “The effect of botulinum toxin type A injection 
on compound muscle action potential in an in vivo rat model,” 
Laryngoscope, 105, No. 2, 144-148 (1995).
52. S. Ando, S. Kobayashi, H. Waki, et al., “Animal model 
of dementia induced by entorhinal synaptic damage and 
partial restoration of cognitive deficits by BDNF and 
carnitine,” J. Neurosci. Res., 70, No. 3, 519-527 (2002).
53. S. Luvisetto, S. Marinelli, O. Rossetto, et al., “Central injection 
of botulinum neurotoxins: behavioural effects in mice,” Behav. 
Pharmacol., 15, No. 3, 233-240 (2004).
54. Z. Lackovic, V. Rebic, and P. F. Riederer,  “Single 
intracerebroventricular injection of botulinum toxin type A 
produces slow onset and long-term memory impairment in 
rats,” J. Neural Transm., 116, No. 10, 1273-1280 (2009).
55. F. J. Lebeda, R. Z. Cer, R. M. Stephens, and U. Mudunuri, 
“Temporal characteristics of botulinum neurotoxin therapy,” 
Expert Rev. Neurother., 10, No. 1, 93-103 (2010).
56. F. Antonucci, C. Rossi, L. Gianfranceschi, et al., “Long-
distance retrograde effects of botulinum neurotoxin A,” J. 
Neurosci., 28, No. 14, 3689-2696 (2008).
57. A. Curra and A. Berardelli, “Do the unintended actions of 
botulinum toxin at distant sites have clinical implications?” 
Neurology, 72, No. 12, 1095-1099 (2009).
58. L. Restani, F. Antonucci, L. Gianfranceschi, et al., “Evidence 
for anterograde transport and transcytosis of botulinum 
neurotoxin A (BoTx/A),” J. Neurosci., 31, No. 44, 1565-1569 
(2011).
59. F. A. Meunier, G. Lisk, D. Sesardic, and J. O. Dolly, 
“Dynamics of motor nerve terminal remodeling unveiled using 
SNARE-cleaving botulinum toxins: the extent and duration 
are dictated by the sites of SNAP-25 truncation,” Mol. Cell. 
Neurosci., 22, No. 4, 454-466 (2003).
60. A. Bogucki, “Serial SFEMG studies of orbicularis oculi muscle 
after the first administration of botulinum toxin,” Eur. J. 
Neurol., 6, No. 4, 461-467 (1999).
61. D. A. Boroff and G. S. Chen, “On the question of permeability 
of the blood-brain barrier to botulinum toxin,” Int. Arch. 
Allergy Appl. Immunol., 48, No. 4, 495-504 (1975).
62. M. Aguggia, “Neurophysiology of pain,” Neurol. Sci., 24, 
Suppl. 2, 57-60 (2003).
63. K. R. Aoki, “Evidence for antinociceptive activity of botulinum 
toxin type A in pain management,” Headache, 43, Suppl 1, 
9-15 (2003).
64. M. J. Welch, J. R. Purkiss, and K. A. Foster, “Sensitivity of 
embryonic rat dorsal root ganglia neurons to Clostridium 
botulinum neurotoxins,” Toxicon, 38, No. 2, 245-258 (2000).
65. P. L. Durham and R. Cady, “Regulation of calcitonin gene-
related peptide secretion from trigeminal nerve cells by 
botulinum toxin type A: implications for migraine therapy,” 
Headache, 44, No. 1, 35-42; discussion -3, (2004).
66. B. Freund and M. Schwartz, “Temporal relationship of muscle 
weakness and pain reduction in subjects treated with botulinum 
toxin A,” J. Pain, 4, No. 3, 159-165 (2003).
67. D. Tarsy and E. R. First, “Painful cervical dystonia: clinical 
features and response to treatment with botulinum toxin,” Mov. 
Disord., 14, No. 6, 1043-1045 (1999).
68. I. Matak, L. Bach-Rojecky, B. Filipović, and Z. Lacković, 
“Behavioral and immunohistochemical evidence for central 
antinociceptive activity of botulinum toxin A,” Neuroscience, 
186, 201-207 (2011).
69. M. Cui, S. Khanijou, J. Rubino, and K. R. Aoki, “Subcutaneous 
administration of botulinum toxin A reduces formalin-induced 
pain,” Pain, 107, Nos. 1/2, 125-133 (2004).
70. S. Luvisetto, S. Marinelli, F. Lucchetti, et al., “Botulinum 
neurotoxins and formalin-induced pain: central vs. peripheral 
effects in mice,” Brain Res., 1082, No. 1, 124-131 (2006).
71. L. Bach-Rojecky, M. Salkovic-Petrisic, and Z. Lackovic, 
“Botulinum toxin type A reduces pain supersensitivity in 
experimental diabetic neuropathy: bilateral effect after 
unilateral injection,” Eur. J. Pharmacol., 633, Nos. 1/3, 10-14 
(2010).
72. C. Favre-Guilmard, M. Auguet, and P. E. Chabrier, “Different 
antinociceptive effects of botulinum toxin type A in 
inflammatory and peripheral polyneuropathic rat models,” Eur. 
J. Pharmacol., 617, Nos. 1/3, 48-53 (2009).
73. L. Bach-Rojecky and Z. Lackovic, “Antinociceptive effect 
of botulinum toxin type a in rat model of carrageenan and 
capsaicin induced pain,” Croat. Med. J., 46, No. 2, 201-208 
(2005).
74. L. Bach-Rojecky, M. Relja, and Z. Lackovic, “Botulinum toxin 
type A in experimental neuropathic pain,” J. Neural Transm., 
112, No. 2, 215-219 (2005).
75. S. Luvisetto, S. Marinelli, S. Cobianchi and F. Pavone, “Anti-
allodynic efficacy of botulinum neurotoxin A in a model of 
neuropathic pain,” Neuroscience, 145, No. 1, 1-4 (2007).
76. S. Marinelli, S. Luvisetto, S. Cobianchi, et al., “Botulinum 
neurotoxin type A counteracts neuropathic pain and facilitates 
functional recovery after peripheral nerve injury in animal 
models,” Neuroscience, 171, No. 1, 316-328 (2010).
77. H. J. Park, Y. Lee, J. Lee, et al., “The effects of botulinum 
toxin A on mechanical and cold allodynia in a rat model of 
neuropathic pain,” Can. J. Anaesth., 53, No. 5, 470-477 (2006).
78. F. Pavone and S. Luvisetto, “Botulinum neurotoxin for 
pain management: insights from animal models,” Toxins, 
2, No. 12, 2890-2913 (2010).
79. L. Bach-Rojecky and Z. Lackovic, “Central origin of the 
antinociceptive action of botulinum toxin type A,” Pharmacol. 
Biochem. Behav., 94, No. 2, 234-238 (2009).
80. W. H. Jost, “Botulinum toxin in multiple sclerosis,” J. Neurol., 
253, Suppl. 1, I16-120 (2006).
81. D. Dressler, F. A. Saberi, and E. R. Barbosa, “Botulinum toxin: 
mechanisms of action,” Arq. Neuropsiquiatr., 63, No. 1, 180-
185 (2005).
82. M. L. Mahowald, J. A. Singh, and D. Dykstra, “Long term 
effects of intra-articular botulinum toxin A for refractory joint 
pain,” Neurotox. Res., 9, Nos. 2/3, 179-188 (2006).
83. G. Lennerstrand, O. A. Nordbo, S. Tian, et al., “Treatment of 
strabismus and nystagmus with botulinum toxin type A. An 
evaluation of effects and complications,” Acta Ophthalmol. 
Scand., 76, No. 1, 27-27 (1998).
84. Z. Nussgens and P. Roggenkamper, “Long-term treatment 
of blepharospasm with botulinum toxin type A,” Ger. J. 
Ophthalmol., 4, No. 6, 363-367 (1995).
85. S. Jitpimolmard, S. Tiamkao, and M. Laopaiboon, “Long term 
results of botulinum toxin type A (Dysport) in the treatment of 
hemifacial spasm: a report of 175 cases,” J. Neurol. Neurosurg. 
Psychiat., 64, No. 6, 751-757 (1998).
86. C. L. Comella, J. Jankovic, and M. F. Brin, “Use of botulinum 
toxin type A in the treatment of cervical dystonia,” Neurology, 
55, No. 12, Suppl. 5, 15-21 (2000).
87. N. Giladi, “The mechanism of action of botulinum toxin 
type A in focal dystonia is most probably through its dual 
NEUROPHYSIOLOGY / НЕЙРОФИЗИОЛОГИЯ.—2015.—T. 47, № 4390
M. GALAZKA, D. SOSZYNSKI, and K. DMITRUK
effect on efferent (motor) and afferent pathways at the 
injected site,” J. Neurol. Sci., 152, No. 2, 132-135 (1997).
88. P. Schnider, E. Moraru, H. Kittler, et al., “Treatment of 
focal hyperhidrosis with botulinum toxin type A: long-term 
follow-up in 61 patients,” Br. J. Dermatol., 145, No. 2, 289-
293 (2001).
89. R. Opavsky, P. Hlustik, P. Otruba, and P. Kanovsky, 
“Sensorimotor network in cervical dystonia and the effect 
of botulinum toxin treatment: a functional MRI study,” J. 
Neurol. Sci., 306, Nos. 1/2, 71-75 (2011).
90. E. C. Lim and R. C. Seet, “Botulinum toxin: description 
of injection techniques and examination of controversies 
surrounding toxin diffusion,” Acta Neurol. Scand., 117, No. 2, 
73-84 (2008).
